PORTFOLIO

The microbiome represents a new area of science with potential to improve human health. At SURI BioTech we untangle the potential of the gut microbiome using rationally selected bacterial strains with clear targets and high efficacy. Our proprietary bacterial strains are developed based on our strong scientific understanding on the metabolic potential of the intestinal microorganisms – with potential applications in multiple applications in infant and adult’s health. BactoKind, our first application, is a food supplement containing a consortium of natural bacterial strains for the alleviation of infant colic.
20% of babies younger than 5 months suffer from infant colic, a functional gastrointestinal disorder characterized by inconsolable crying, over 3 hours a day, 3 times a week, which severely impairs quality of life of the parents, and can also trigger maternal post-partum depression. BactoKind is the first microbial solution for infant colic with a clear mechanism of action and will offer relief to the infant’s pain and improve parents’ well-being.

Our project focused primarily on product development, with the objective of optimizing fermentation yields and establishing upscaling processes for our strains. Through our own experimentation and collaboration with Agroscope, we have successfully achieved our goal of demonstrating the scalability of the product. SURI BioTech GmbH was incorporated in March 2023 and obtained the official ETH spin-off label in April 2023. SURI BioTech was able to secure BactoKind’s trademark in EU, Switzerland and UK. Furthermore, we have filed a follow-on patent to protect the innovative formulation. Looking forward to market entry, we are currently preparing the regulatory dossier of our strains and closing partnership deals with industrial partners. We are in parallel establishing collaborations with researchers from public research institutions to run intervention trials and evaluate the efficacy of our formulation. Our next milestone aims at generating first revenues through distribution and licensing deals by the end of 2024.